The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to update their vaccines.

In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the Center for Biologics Evaluation and research at the FDA, and Dr. Martin Makary, FDA commissioner, explained their plan for how the FDA will evaluate and recommend COVID-19 vaccines going forward.